Top ▲
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 1130 | 16p13.13 | CIITA | class II major histocompatibility complex transactivator | |
Mouse | - | 1155 | 16 A1 | Ciita | class II transactivator | |
Rat | - | - | 10 q11 | Ciita | class II |
Database Links ![]() |
|
Alphafold | P33076 (Hs), P79621 (Mm) |
Ensembl Gene | ENSG00000179583 (Hs), ENSMUSG00000022504 (Mm), ENSRNOG00000002659 (Rn) |
Entrez Gene | 4261 (Hs), 12265 (Mm), 85483 (Rn) |
Human Protein Atlas | ENSG00000179583 (Hs) |
KEGG Gene | hsa:4261 (Hs), mmu:12265 (Mm), rno:85483 (Rn) |
OMIM | 600005 (Hs) |
Pharos | P33076 (Hs) |
UniProtKB | P33076 (Hs), P79621 (Mm) |
Wikipedia | CIITA (Hs) |
Immunopharmacology Comments |
CIITA is a transcriptional coactivator for the transcription factor RFX5 [5]. Evidence suggests that it is involved in expression of HLA class II genes [1-2,4]. CIITA mRNA is found only in human leukocyte antigen (HLA) system class II-positive cell lines and tissues. In humans, genetic variations in CIITA are associated with differential expression of MHC-II and susceptibility to autoimmune diseases, although the contribution that altered expression plays in autoimmune pathologies has not been fully resolved [7]. It is hypothesised that cytokine-driven JAK-mediated signals downregulate CIITA and MHC-II expression to enable host immune evasion by chronic myeloid leukemia stem/progenitor cells that persist after tyrosine kinase inhibitor therapy and are a relapse risk [6]. |
Cell Type Associations | ||||||
|
Immuno Process Associations | ||||||||||||
|
||||||||||||
|
Immuno Disease Associations | ||||||||||
|
Physiological Functions Comments | |
Transactivator of class II major histocompatibility complex genes. |
Clinically-Relevant Mutations and Pathophysiology ![]() |
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
1. Harton JA, Ting JP. (2000) Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol, 20 (17): 6185-94. [PMID:10938095]
2. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W. (2004) Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol, 34 (6): 1513-25. [PMID:15162420]
3. Li L, Yu H, Jiang Y, Deng B, Bai L, Kijlstra A, Yang P. (2016) Genetic Variations of NLR family genes in Behcet's Disease. Sci Rep, 6: 20098. [PMID:26833430]
4. Mach B, Steimle V, Reith W. (1994) MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol Rev, 138: 207-21. [PMID:8070816]
5. Scholl T, Mahanta SK, Strominger JL. (1997) Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc Natl Acad Sci USA, 94 (12): 6330-4. [PMID:9177217]
6. Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL et al.. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129 (2): 199-208. [PMID:27793879]
7. Yau AC, Piehl F, Olsson T, Holmdahl R. (2017) Effects of C2ta genetic polymorphisms on MHC class II expression and autoimmune diseases. Immunology, 150 (4): 408-417. [PMID:27861821]